- Home
- CNTB vs PSNL Comparison
CNTB vs PSNL Comparison
Compare CNTB & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | PSNL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 872.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNTB | PSNL |
|---|---|---|
| Price | $2.73 | $8.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.50 | ★ $10.71 |
| AVG Volume (30 Days) | 186.1K | ★ 1.5M |
| Earning Date | 03-31-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $762,000.00 | ★ $69,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24,739.01 | $20.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $2.83 |
| 52 Week High | $3.28 | $11.40 |
Technical Indicators
Market Signals| Indicator | CNTB | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 45.67 |
| Support Level | $2.11 | $7.68 |
| Resistance Level | $2.65 | $9.10 |
| Average True Range (ATR) | 0.21 | 0.57 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 85.37 | 26.07 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.